MX392267B - Metodos para evaluar el riesgo de desarrollar cancer de mama. - Google Patents

Metodos para evaluar el riesgo de desarrollar cancer de mama.

Info

Publication number
MX392267B
MX392267B MX2017004127A MX2017004127A MX392267B MX 392267 B MX392267 B MX 392267B MX 2017004127 A MX2017004127 A MX 2017004127A MX 2017004127 A MX2017004127 A MX 2017004127A MX 392267 B MX392267 B MX 392267B
Authority
MX
Mexico
Prior art keywords
risk
methods
breast cancer
developing breast
evaluating
Prior art date
Application number
MX2017004127A
Other languages
English (en)
Spanish (es)
Other versions
MX2017004127A (es
Inventor
Richard Allman
Original Assignee
Genetic Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014903898A external-priority patent/AU2014903898A0/en
Application filed by Genetic Tech Limited filed Critical Genetic Tech Limited
Publication of MX2017004127A publication Critical patent/MX2017004127A/es
Publication of MX392267B publication Critical patent/MX392267B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
MX2017004127A 2014-09-30 2015-09-29 Metodos para evaluar el riesgo de desarrollar cancer de mama. MX392267B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014903898A AU2014903898A0 (en) 2014-09-30 Methods for assessing the risk of developing breast cancer
PCT/AU2015/050583 WO2016049694A1 (en) 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer

Publications (2)

Publication Number Publication Date
MX2017004127A MX2017004127A (es) 2017-10-24
MX392267B true MX392267B (es) 2025-03-24

Family

ID=55629155

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004127A MX392267B (es) 2014-09-30 2015-09-29 Metodos para evaluar el riesgo de desarrollar cancer de mama.

Country Status (11)

Country Link
US (2) US10920279B2 (enExample)
EP (1) EP3201360A4 (enExample)
JP (1) JP6820838B2 (enExample)
KR (1) KR102334702B1 (enExample)
CN (1) CN107002138B (enExample)
AU (2) AU2015327756B2 (enExample)
CA (1) CA2962691C (enExample)
IL (1) IL251376B (enExample)
MX (1) MX392267B (enExample)
SG (1) SG11201702416YA (enExample)
WO (1) WO2016049694A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166738A1 (en) 2005-11-29 2007-07-19 Perlegen Sciences, Inc. Markers for breast cancer
DK2438193T3 (en) 2009-06-01 2015-10-19 Genetic Technologies Ltd Methods for assessing the risk of breast cancer
US10920279B2 (en) 2014-09-30 2021-02-16 Genetic Technologies Limited Method for modifying a treatment regimen of a human female subject
US20200102617A1 (en) * 2017-01-24 2020-04-02 Genetic Technologies Limited Improved Methods For Assessing Risk of Developing Breast Cancer
US12577622B2 (en) 2017-06-02 2026-03-17 Myriad Genetics, Inc. Detecting cancer risk
US12637716B1 (en) 2017-06-02 2026-05-26 Myriad Genetics, Inc. Detecting cancer risk
KR20200100614A (ko) * 2017-10-13 2020-08-26 지네틱 테크놀로지스 리미티드 유방암 발생의 위험도 평가의 방법
CN108060229A (zh) * 2017-12-27 2018-05-22 沃森克里克（北京）生物科技有限公司 一种TERT基因rs10069690位点SNP核酸质谱检测方法
CN110628912A (zh) * 2019-11-06 2019-12-31 上海韦翰斯生物医药科技有限公司 检测多态性的引物及方法
KR102169699B1 (ko) * 2019-12-27 2020-10-23 주식회사 클리노믹스 유전자 검사를 위한 맞춤형 유전자칩 및 이의 제작 방법
KR20230019872A (ko) * 2020-05-27 2023-02-09 지네틱 테크놀로지스 리미티드 코로나바이러스 감염에 대한 중증 반응의 발생 위험을 평가하는 방법
CN112687330A (zh) * 2020-12-29 2021-04-20 北京易奇科技有限公司 一种乳腺癌患者携带胚系致病变异的风险预测系统
CN115762635A (zh) * 2021-12-27 2023-03-07 河北北方学院附属第一医院 基于分子标记的用于肝癌筛查和风险预测的系统及应用
CN116469552A (zh) * 2022-07-28 2023-07-21 复旦大学附属肿瘤医院 一种用于乳腺癌多基因遗传风险评估的方法和系统
US20250149176A1 (en) * 2023-11-08 2025-05-08 Optum Services (Ireland) Limited Model-based risk prediction and treatment pathway prioritization

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147035A (en) 1978-05-10 1979-11-16 Minolta Camera Co Ltd Tessar type photographic lens placed behind aperture
US4240608A (en) 1979-11-02 1980-12-23 Acf Industries, Incorporated Controlled float seat arrangement for expanding gate valves
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
DE69739357D1 (de) 1996-06-04 2009-05-28 Univ Utah Res Found Überwachung der hybridisierung während pcr
DE69704031T2 (de) 1996-11-07 2001-06-13 Oklahoma Medical Research Foundation, Oklahoma Test zur diagnose eines erhöhten brustkrebs-risikos
EP1155361A2 (en) 1998-12-02 2001-11-21 Kiva Genetics, Inc. Methods to reduce variance in treatment studies using genotyping
US20020123095A1 (en) 1999-10-20 2002-09-05 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
EP1305446A4 (en) 2000-07-25 2004-10-06 Dz Genes Llc DIAGNOSIS OF ECNOS PROMOTER POLYMORPHISMS
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
US6872533B2 (en) 2001-07-27 2005-03-29 The Regents Of The University Of California STK15 (STK6) gene polymorphism and methods of determining cancer risk
US7529685B2 (en) 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
JP2005532780A (ja) 2001-09-19 2005-11-04 インタージェネティックス インコーポレイテッド 発癌リスク層別化のための遺伝的解析
US20040023237A1 (en) 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6897025B2 (en) 2002-01-07 2005-05-24 Perlegen Sciences, Inc. Genetic analysis systems and methods
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
US7135286B2 (en) 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US20040210400A1 (en) 2003-01-27 2004-10-21 Perlegen Sciences, Inc. Analysis methods for individual genotyping
US20040191783A1 (en) 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US20050019787A1 (en) 2003-04-03 2005-01-27 Perlegen Sciences, Inc., A Delaware Corporation Apparatus and methods for analyzing and characterizing nucleic acid sequences
US7124033B2 (en) 2003-04-30 2006-10-17 Perlegen Sciences, Inc. Method for identifying matched groups
US20040229224A1 (en) 2003-05-13 2004-11-18 Perlegen Sciences, Inc. Allele-specific expression patterns
US20040241657A1 (en) 2003-05-28 2004-12-02 Perlegen Sciences, Inc. Liver related disease compositions and methods
WO2005014846A2 (en) * 2003-07-24 2005-02-17 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20050136438A1 (en) 2003-09-04 2005-06-23 David Ralph Genetic analysis for stratification of cancer risk
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20070166738A1 (en) 2005-11-29 2007-07-19 Perlegen Sciences, Inc. Markers for breast cancer
US20080009419A1 (en) 2006-06-23 2008-01-10 Intergenetics, Inc. Genetic models for stratification of cancer risk
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
AU2008231425B2 (en) * 2007-03-26 2014-03-20 Decode Genetics Ehf Genetic variants on Chr2 and Chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP2535425A1 (en) 2007-05-25 2012-12-19 Decode Genetics EHF. Variantes génétiques sur les chr 10q26 utilisées comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
CA2693783A1 (en) 2007-07-11 2009-01-15 Intergenetics, Inc. Genetic models for stratification of cancer risk
WO2009097270A2 (en) * 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
US20100042438A1 (en) 2008-08-08 2010-02-18 Navigenics, Inc. Methods and Systems for Personalized Action Plans
GB2477868A (en) 2008-09-12 2011-08-17 Navigenics Inc Methods and systems for incorporating multiple environmental and genetic risk factors
DK2438193T3 (en) 2009-06-01 2015-10-19 Genetic Technologies Ltd Methods for assessing the risk of breast cancer
JP2012531210A (ja) * 2009-06-25 2012-12-10 イェール ユニバ−シティ− Ｂｒｃａ１における一塩基多型および癌のリスク
WO2013151413A1 (en) * 2012-04-02 2013-10-10 Infovalley Life Science Sdn. Bhd. Methods and compositions for determining increased risk for breast cancer
US10920279B2 (en) 2014-09-30 2021-02-16 Genetic Technologies Limited Method for modifying a treatment regimen of a human female subject
US20200102617A1 (en) 2017-01-24 2020-04-02 Genetic Technologies Limited Improved Methods For Assessing Risk of Developing Breast Cancer
US10609708B1 (en) 2017-06-27 2020-03-31 Sprint Spectrum L.P. Use of TDD special subframe for transmission of small quantity of data
KR20200100614A (ko) 2017-10-13 2020-08-26 지네틱 테크놀로지스 리미티드 유방암 발생의 위험도 평가의 방법

Also Published As

Publication number Publication date
AU2018202299A1 (en) 2018-04-26
CA2962691A1 (en) 2016-04-07
IL251376A0 (en) 2017-05-29
KR20170063977A (ko) 2017-06-08
US10683549B2 (en) 2020-06-16
IL251376B (en) 2022-09-01
US20160222469A1 (en) 2016-08-04
SG11201702416YA (en) 2017-04-27
AU2015327756B2 (en) 2018-01-04
US20180305764A1 (en) 2018-10-25
AU2018202299B9 (en) 2020-03-05
US10920279B2 (en) 2021-02-16
JP2017529859A (ja) 2017-10-12
MX2017004127A (es) 2017-10-24
AU2015327756A1 (en) 2017-04-13
CN107002138B (zh) 2022-06-14
KR102334702B1 (ko) 2021-12-06
JP6820838B2 (ja) 2021-01-27
CA2962691C (en) 2023-05-23
CN107002138A (zh) 2017-08-01
WO2016049694A1 (en) 2016-04-07
AU2018202299B2 (en) 2019-10-24
EP3201360A1 (en) 2017-08-09
EP3201360A4 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
MX2017004127A (es) Metodos para evaluar el riesgo de desarrollar cancer de mama.
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
EP4428863A3 (en) Methods and compositions for determining ploidy
EP4202441A3 (en) Gene expression profile in macrophages for the diagnosis of cancer
MX2018009274A (es) Cancer.
GB201105129D0 (en) Compositions and methods for treating, diagnosing and monitoring disease
UA104426U (uk) Спосіб прогнозування зрощення перелому
UA95580U (uk) Спосіб прогнозування зрощення перелому
UA96688U (uk) Спосіб прогнозування зрощення перелому
UA96926U (uk) Спосіб прогнозування зрощення перелому
UA95602U (uk) Спосіб прогнозування зрощення перелому
UA96640U (uk) Спосіб прогнозування зрощення перелому
UA96691U (uk) Спосіб прогнозування зрощення перелому
UA95674U (uk) Спосіб прогнозування зрощення перелому
UA96596U (uk) Спосіб прогнозування зрощення перелому
UA96639U (uk) Спосіб прогнозування зрощення перелому
UA95657U (uk) Спосіб прогнозування зрощення перелому
UA96670U (uk) Спосіб прогнозування зрощення перелому
UA107749U (uk) Спосіб прогнозування зрощення перелому
UA95641U (uk) Спосіб прогнозування зрощення перелому
UA95656U (uk) Спосіб прогнозування зрощення перелому
UA95658U (uk) Спосіб прогнозування зрощення перелому
UA107750U (uk) Спосіб прогнозування зрощення перелому
UA106731U (uk) Спосіб прогнозування зрощення перелому
UA94790U (uk) Спосіб прогнозування зрощення перелому